Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 8, 2013 (14 years ago)

Meprobamate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Watson Laboratories Inc. is recalling meprobamate because an out of specification result for an impurity diphenyl sulfone .

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Meprobamate, Tablets USP, 200 mg, 100 tablets; Rx only; Manufactured By: Watson Laboratories, Inc., Corona, CA 92800 USA; 173266; . Distributed by: Watson Pharma, Inc., NDC 9591-5239-01

Affected NDC 9591-5239-01

Compare with the code on your package — it is the most precise check available.

Recalling firm
Watson Laboratories Inc
NDC code
9591-5239-01
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-203-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Watson Laboratories Inc

All 2013 recalls
Class II · Moderate risk

Carisoprodol Tablets

Presence of Foreign Substance; metal particulates were visually observed in the tablets.

Terminated Particulate / foreign matter Watson Laboratories Inc NDC 0591-5513-05 D-397-2014
Class II · Moderate risk

Oxycodone and Acetaminophen Tablets

Presence of Foreign Tablets/Capsules: 20 tablets of Oxycodone/APAP 7.5/500 mg were found in a sealed 100 count bottle of Oxycodone and Acetaminophen Tablets, USP 10/650 mg lot# 705791A.

Terminated Particulate / foreign matter Watson Laboratories Inc NDC 0591-0825-01 D-66251-001

Other impurity / degradation recalls from 2013

All impurity / degradation recalls
Class II · Moderate risk

Hydralazine HCL Tablets

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 00182-0555-89 D-1075-2014
Class II · Moderate risk

Hydralazine HCL Tablets

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 00182-0554-89 D-1074-2014
Class III · Low risk

Cetirizine Hydrochloride Syrup

Failed impurities/degradation specifications; out of specification for the known impurity 4-chlorobenzophenone.

Terminated Impurity / degradation Qualitest Pharmaceuticals NDC 0603-9063-54 D-394-2014
Class III · Low risk

Folic Acid Injection

Failed Impurities/Degradation specifications: out-of-specification results 14 & 15 month time point

Terminated Impurity / degradation Fresenius Kabi USA, LLC NDC 63323-184-11 D-379-2014